SCHEMBL21911291

SCHEMBL21911291

CCc1cc(F)ccc1C(c1ccc(F)cc1)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.36
ALDH1A1 P00352 2/20 0.36
AGBL2 Q5U5Z8 1/20 0.36
HTT P42858 3/20 0.35
ALOX15 P16050 2/20 0.35
MAPT P10636 2/20 0.35
KDM4E B2RXH2 1/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
HSD17B10 Q99714 1/20 0.35
RXRA P19793 1/20 0.34
TACR1 P25103 2/20 0.34
AOC3 Q16853 1/20 0.33
DAO P14920 1/20 0.33
ALOX12 P18054 1/20 0.33
F2RL1 P55085 3/20 0.33
POLB P06746 1/20 0.33
GPR55 Q9Y2T6 1/20 0.33
MEN1 O00255 1/20 0.33
PKM P14618 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21911306 0.91 PSEN1 (0.42) AGBL2MAPK1RXRA
SCHEMBL21910188 0.83 ALDH1A1 (0.41) LMNAALDH1A1HTTMAPTKDM4E
SCHEMBL25482219 0.83 DAO (0.41) LMNAALDH1A1AGBL2HTTALOX15
SCHEMBL23055121 0.79 AGBL2 (0.38) LMNAALDH1A1AGBL2MAPTMAPK1
SCHEMBL13863848 0.78 AGBL2 (0.38) AGBL2MAPTKDM4ERXRAF2RL1
SCHEMBL30910896 0.78 F2RL1 (0.45) LMNAALDH1A1AGBL2HTTALOX15
SCHEMBL21831133 0.78 F2RL1 (0.45) LMNAALDH1A1AGBL2HTTALOX15
SCHEMBL21911295 0.78 HRH4 (0.42) LMNAHTTMAPK1POLBMEN1
SCHEMBL21911292 0.77 NFE2L2 (0.37) MAPTKDM4ETACR1AOC3MEN1
SCHEMBL30133776 0.75 F2RL1 (0.41) LMNAAGBL2HTTALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3814348-B9 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-11-01 EP disclosed
EP-3814348-B1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-08-02 EP disclosed
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2023-08-01 US disclosed
US-20230061608-A1 SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL MYERS SQUIBB CO (US) 2023-03-02 US disclosed
WO-2021041588-A1 SUBSTITUTED PYRIDOPYRIMIDINONYL COMPOUNDS USEFUL AS T CELL ACTIVATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2021-03-04 WO disclosed
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators BRISTOL-MYERS SQUIBB COMPANY (US) 2020-06-02 US disclosed
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS SYNGENE INTERNATIONAL LIMITED (IN) 2020-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200109140-A1 SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG LMNA 1862/4885ALDH1A1 3814/4885AGBL2 4474/4885
US-20230061608-A1 SUBSTITUTED QUINOLINONYL PIPERAZINE COMPOUNDS USEFUL AS T CELL ACTIVATORS DGKZ, DGKA, DGKG LMNA 3271/4885ALDH1A1 3975/4885AGBL2 3773/4885
US-11713316-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG LMNA 1862/4885ALDH1A1 3814/4885AGBL2 4474/4885
US-10669272-B2 Substituted naphthyridinone compounds useful as T cell activators DGKZ, DGKA, DGKG LMNA 1862/4885ALDH1A1 3814/4885AGBL2 4474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.